Will Diplomat Pharmacy Incorporated (NYSE:DPLO) Run Out of Steam Soon? Short Interest Is Down

January 17, 2018 - By Ellis Scott

 Will Diplomat Pharmacy Incorporated (NYSE:DPLO) Run Out of Steam Soon? Short Interest Is Down

Investors sentiment decreased to 1.44 in Q3 2017. Its down 0.83, from 2.27 in 2017Q2. It turned negative, as 22 investors sold Diplomat Pharmacy, Inc. shares while 37 reduced holdings. 21 funds opened positions while 64 raised stakes. 49.42 million shares or 3.34% more from 47.82 million shares in 2017Q2 were reported.
Public Sector Pension Invest Board owns 30,139 shares or 0% of their US portfolio. Morgan Stanley invested 0% of its portfolio in Diplomat Pharmacy, Inc. (NYSE:DPLO). First Mercantile Trust Com has invested 0.09% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Metropolitan Life Insur Ny has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Raymond James accumulated 37,024 shares or 0% of the stock. First Interstate Bank invested in 150 shares or 0% of the stock. 97,613 were accumulated by Rhumbline Advisers. Engineers Gate Manager Lp, a New York-based fund reported 67,805 shares. First Trust Advsrs Limited Partnership invested in 75,450 shares or 0% of the stock. Iguana Health Management Llc has 0.69% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 60,000 shares. Carroll Fincl Assoc invested 0% of its portfolio in Diplomat Pharmacy, Inc. (NYSE:DPLO). The Washington-based Parametric Port Associates Ltd Liability has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Louisiana State Employees Retirement Systems has invested 0.02% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Schwab Charles Invest Mngmt Inc owns 294,497 shares. Ftb invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO).

The stock of Diplomat Pharmacy Incorporated (NYSE:DPLO) registered a decrease of 22.2% in short interest. DPLO’s total short interest was 5.00 million shares in January as published by FINRA. Its down 22.2% from 6.43 million shares, reported previously. With 1.51 million shares average volume, it will take short sellers 3 days to cover their DPLO’s short positions.

The stock increased 1.41% or $0.36 during the last trading session, reaching $25.88. About 549,485 shares traded. Diplomat Pharmacy, Inc. (NYSE:DPLO) has declined 40.48% since January 17, 2017 and is downtrending. It has underperformed by 57.18% the S&P500.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company has market cap of $1.89 billion. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It has a 221.2 P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Ratings Coverage

Among 13 analysts covering Diplomat Pharmacy (NYSE:DPLO), 5 have Buy rating, 1 Sell and 7 Hold. Therefore 38% are positive. Diplomat Pharmacy had 34 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by Robert W. Baird given on Tuesday, August 8. The firm has “Neutral” rating given on Wednesday, October 14 by Bank of America. The stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) has “Market Perform” rating given on Thursday, November 3 by Cowen & Co. On Tuesday, August 4 the stock rating was maintained by Leerink Swann with “Outperform”. The rating was maintained by Needham with “Buy” on Thursday, October 5. The firm earned “Market Perform” rating on Tuesday, November 7 by Leerink Swann. Robert W. Baird maintained the stock with “Outperform” rating in Monday, September 18 report. UBS initiated Diplomat Pharmacy, Inc. (NYSE:DPLO) rating on Wednesday, October 21. UBS has “Buy” rating and $35 target. The firm has “Neutral” rating given on Thursday, November 3 by Mizuho. Leerink Swann downgraded the stock to “Mkt Perform” rating in Thursday, November 3 report.

More important recent Diplomat Pharmacy, Inc. (NYSE:DPLO) news were published by: Prnewswire.com which released: “Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®” on January 15, 2018, also Prnewswire.com published article titled: “This Morning’s Technical Outlook on Generic Drugs Stocks — Versartis …”, Prnewswire.com published: “Diplomat Completes Acquisition of LDI Integrated Pharmacy Services, Secures …” on December 20, 2017. More interesting news about Diplomat Pharmacy, Inc. (NYSE:DPLO) was released by: Crainsdetroit.com and their article: “Diplomat Pharmacy Chairman and CEO Phil Hagerman retires” with publication date: January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: